Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization

Journal of Immunology

Volumn 165, Issue 8, 2000, Pages 4748-4755

  Loirat, D ^a   Lemonnier, F A ^a   Michel, M L ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD8 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HLA A ANTIGEN; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; EPITOPE; HEPATITIS B VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNIZATION; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE; ALLELE; ANIMAL; ANTIGEN PRESENTATION; BIOSYNTHESIS; CD8+ T LYMPHOCYTE; CYTOTOXICITY; GENETICS; HEPATITIS B VIRUS; IMMUNOLOGY; METABOLISM; PROTEIN BINDING; SECRETION;

ALLELES; ANIMALS; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; MICE; MICE, TRANSGENIC; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VIRAL ENVELOPE PROTEINS;

EID: 0034666835     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.8.4748     Document Type: Article

References (57)

1. Hepatitis B virus infection
2. The treatment of chronic viral hepatitis
3. Hepatitis B virus immunopathogenesis
4. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection
5. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice
6. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state
7. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes
8. Viral cross talk: Intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver
9. Specific vaccine therapy in chronic hepatitis B: Induction of T cell proliferative responses specific for envelope antigens
10. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans
11. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus: The CY1899 T Cell Vaccine Study Group
12. DNA vaccines
13. DNA based immunization for hepatitis B induces continuous secretion of antigen and high levels of circulating antibody
14. DNA-mediated immunization to the hepatitis B surface antigen in mice: Aspects of the humoral response mimic hepatitis B viral infection in humans
15. DNA-mediated immunization to hepatitis B surface antigen: Longevity of primary response and effect of boost
16. In vivo induction of specific cytotoxic T lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis B surface antigen
17. Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-γ-secreting T cells after DNA-based immunization
18. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein
19. Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA-based immunization
20. Muscle-specific expression of hepatitis B surface antigen: No effect on DNA-raised immune responses
21. Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection
22. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein
23. 2m double knockout mice
24. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection
25. H-2 class I knockout, HLA-A2.1-transgenic mice: A versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies
26. + cytotoxic T-cell epitopes
27. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes
28. DNA-based immunization against the envelope proteins of the hepatitis B virus
29. Immunization with a plasmid encoding a modified hepatitis B surface antigen carrying the receptor binding site for hepatocytes
30. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Polspecific CD8 T cells in HIV-1-positive individuals
31. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants
32. + T cells to antigen stimulation in vivo
33. Hepatitis B virus large surface protein is not secreted but is immunogenic when selectively expressed by recombinant vaccinia virus
34. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice
35. Protective cellular immunity: Cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization
36. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenicity in mice
37. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination
38. Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: Implications on immunogenicity and immunodominance
39. Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model
40. Superdominance among immunodominant H-2Kb-restricted epitopes and reversal by dendritic cell-mediated antigen delivery
41. The composition of a primary T cell response is largely determined by the timing of recruitment of individual T cell clones
42. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL
43. Selectivity of MHC-encoded peptide transporters from human, mouse and rat
44. Immunodominance in the CTL response against minor histocompatibility antigens: Interference between responding T cells, rather than with presentation of epitopes
45. + T cells associated with the control of infection
46. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients
47. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response
48. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen
49. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes
50. Proteasomes can either generate or destroy MHC class I epitopes: Evidence for nonproteasomal epitope generation in the cytosol
51. Human transporters associated with antigen processing (TAPs) select epitope precursor peptides for processing in the endoplasmic reticulum and presentation to T cells
52. Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes
53. Human T cell response to the surface antigen of hepatitis B virus (HBsAg): Endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen
54. Similar as well as distinct MHC class I-binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen
55. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections
56. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B
57. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection